MOMA-313 is a potent, selective Polθ inhibitor that enhances response to PARP inhibition in HR-deficient tumor models

MOMA Therapeutics is pleased to be attending this year’s EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. Our Vice President, Biology and Translational Sciences, Erica Evans, will…

Read More